Third-generation CARs have two signaling domains and a CD3ζ chain, such as CD3ζ–CD28–OX40, which, compared to second-generation CARs, provides increased activation signals, cytokine production, and anti-tumor activity in these cells (4). The gene discussed is CD28; the disease is neoplasm.